The tumor or immune cell expression of Programmed cell Death-Ligand 1 (PD-L1), assessed by immunohistochemistry, is a standard method to select patients for treatment with ICIs, but has limited predictivity and standardization [49,50]. This evidence concerns the gene CD274 and neoplasm.